Altre lingue Genome & Company

Azioni

A314130

KR7314130006

Prezzo di chiusura Korea S.E. Altri mercati azionari 00:00:00 17/07/2024			Variaz. 5gg	Var. 1 gen.
9.640 ^KRW	+15,73%		+15,73%	-22,82%

24/01	Genome & Company annuncia i risultati positivi dello studio clinico di fase 2 della combinazione di GEN-001 e Bavencio®? per il trattamento del cancro gastrico, presentati all'ASCO GI.	CI
2023	Genome & Company annuncia risultati positivi dall'analisi ad interim dello studio di fase II Gen-001 più Avelumab (Bavencio®?)	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI	24/01
Genome & Company Announces Positive Results from Interim Analysis of Gen-001 Plus Avelumab (Bavencio®?) Phase II Trial	19/05/23
Genome & Company announced that it has received KRW 23 billion in funding from a group of investors	07/04/23
Genome & Company announced that it expects to receive KRW 23 billion in funding from a group of investors	05/04/23
Genome & Company announced that it has received KRW 34.34975035 billion in funding from a group of investors	02/09/22
Genome & Company announced that it expects to receive KRW 34.34975035 billion in funding from a group of investors	18/08/22
Genome and Company Announces Clinical Trial Collaboration with Merck & Co., Inc	04/03/22
Microbiome CDMO, List Labs, Partners with Genome And Company, to Create Global Microbiome Research, Development, and Manufacturing Powerhouse	21/09/21
Genome & Company(KOSDAQ:A314130) added to S&P Global BMI Index	20/09/21
Genome & Company agreed to acquire a 60% stake in List Biological Laboratories, Inc. for $27 million.	08/09/21
Genome and Company Signs Second Clinical Trial Collaboration and Supply Agreement (Phase 2) with Merck Kgaa, Darmstadt, Germany and Pfizer for Immuno-Oncology Microbiome Study	09/03/21
Genome & Company and Debiopharm Join Forces to Create New Highly Specific Therapies for Cancer Patients	25/02/21
Genome & Company Announces First Patient Dosed in Phase 1/1B Study of GEN-001	27/10/20
Genome & Company announced that it expects to receive KRW 19.99999001 billion in funding from Korea Development Bank, Investment Arm	26/08/20
Scioto Biosciences, Inc. announced that it has received $26.5 million in funding from Genome & Company and other investors	11/08/20
Scioto Biosciences, Inc. announced that it expects to receive $6.50074 million in funding	07/08/20
Genome & Company announced that it has received KRW 4.00002 billion in funding	25/06/20
Genome & Company announced that it expects to receive KRW 4.00002 billion in funding	17/06/20
Genome & Company announced that it has received KRW 3.62991 billion in funding	24/04/20
Genome & Company Receives FDA IND Clearance for GEN-001, its First Anti-Cancer Microbiome Therapeutic	20/04/20

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Genome & Company

Azioni

A314130

KR7314130006

Altre lingue

Filtri